Novartis Heart-Trial Failure Raises Bar for Next Study Results — Market Talk
Novartis's heart-trial failure means investors' attention now shifts to upcoming results from another late-stage study of a drug acquired as part of the company's $12 billion Avidity Biosciences deal, Jefferies analysts say in a research note. To justify the price of the Avidity deal, the trial nee…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.